Latest Nasdaq Listings News

Ovanti Limited’s U.S. BNPL arm, Flote, has signed a Letter of Intent with Nasdaq-listed Miluna Acquisition Corp for a $300 million valuation, aiming for a Nasdaq listing while preserving Ovanti’s majority ownership.

Aurora Energy Metals and Eagle Energy Metals have agreed to extend the option period for Eagle's acquisition of the Aurora Uranium Project to mid-2026, adjusting milestone timings due to US government shutdown delays impacting Eagle's Nasdaq listing.

Alliance Nickel has confirmed the technical strength of its NiWest project while navigating market headwinds and Stellantis’ offtake renegotiation, as it pursues a Nasdaq listing via SPAC to tap US capital markets.

Alliance Nickel’s binding offtake agreement with Stellantis is terminated due to missed milestones amid tough nickel market conditions, yet renegotiation talks signal ongoing partnership potential.

Light & Wonder, Inc. is set to extend its substantial share repurchase program to include its ASX-listed CHESS Depositary Interests starting November 7, 2025, coinciding with its planned Nasdaq delisting.

Almonty Industries reported a strong net income in Q3 2025, driven by a significant non-cash warrant gain, while advancing the ramp-up of its flagship Sangdong Mine amid rising tungsten demand.

Almonty Industries reversed prior losses with a Q3 2025 profit, successfully listed on Nasdaq, and announced a strategic acquisition in Montana, expanding its tungsten footprint.

Trigg Minerals reports a major geological reinterpretation at its Antimony Canyon Project, defining a substantial exploration target, while expanding its US critical minerals portfolio with key acquisitions and strong funding.

Opthea has significantly reduced its operating costs and settled a key financial liability, positioning itself for a strategic review aimed at unlocking shareholder value.

Trigg Minerals has initiated the process for a Nasdaq dual listing via an American Depositary Receipt program, aiming to tap into the world’s largest capital market. The company also raised A$2.5 million from Tribeca Investment Partners, reinforcing its growth strategy.

Island Pharmaceuticals has completed its acquisition of the broad-spectrum antiviral Galidesivir and is progressing regulatory discussions with the FDA to fast-track approval using the Animal Rule, backed by compelling preclinical data.

Eclipse Metals has advanced its Greenland rare earths project with expanded drilling and a key licence renewal, while preparing for a NASDAQ dual listing to tap North American investors.